Publications, Pharmaceutical

Nasal Drug Development, Trends and Challenges with Nasal Formulations

The confluence of COVID-19, growing recognition of the potential for nose-to-brain drug delivery and the recent success of rapid rescue remedies makes it an exciting time to be working in nasal drug delivery.

This Q&A considers the critical factors that influence nasal drug product development and current trends in formulation practice and science.

The need for a better understanding of precisely where to target nasal drug delivery, and how, is highlighted, along with requirements for better models of mucociliary clearance to tackle the challenge of improving retention. Going forward it is anticipated that nasal drug delivery will be used more, and for a wider range of drugs, notably vaccines and other biologics including mRNA and antibodies.

Download the Nasal Drug Delivery Q&A
Author(s): Dr Irene Rossi
25 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out MORE ABOUT NASAL DRUG DELIVERY EXPERTISE

This Might Also Be of Interest

26 Oct 2021

Using digital healthcare to improve patient compliance and adherence

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
16 Sep 2021

Introducing PureHale® for targeted upper respiratory tract care

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
9 Sep 2021

Aptar Pharma talks targeted drug delivery to the upper airways

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
17 Jun 2021

Drug Repurposing: A More Efficient Approach to Drug Development?

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 14 15 16 17 18 25

Request Access

Close

Requesting access to Nasal Drug Development, Trends and Challenges with Nasal Formulations.

  • This field is for validation purposes and should be left unchanged.
Back To Top